Evidence map›Paper›PMID 39588080›Full record

ArticleERJ open research2024

Efficacy of tezepelumab in patients with severe asthma and persistent airflow obstruction.

Elliot Israel, Mario Castro, Christopher S Ambrose, Jean-Pierre Llanos, Nestor A Molfino, Nicole L Martin, Sandhia S Ponnarambil, Neil Martin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ERJ open research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elliot IsraelPulmonary and Critical Care Medicine, Allergy and Immunology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA.
Mario CastroDivision of Pulmonary, Critical Care and Sleep Medicine, University of Kansas School of Medicine, Kansas City, KS, USA.
Christopher S AmbroseRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD, USA.
Jean-Pierre LlanosGlobal Medical Affairs, Amgen, Thousand Oaks, CA, USA.ORCID https://orcid.org/0000-0002-7785-6881
Nestor A MolfinoGlobal Development, Amgen, Thousand Oaks, CA, USA.
Nicole L MartinBiometrics, Late-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Waltham, MA, USA.
Sandhia S PonnarambilLate-stage Development, Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.ORCID https://orcid.org/0009-0008-8310-6041
Neil MartinRespiratory and Immunology, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Persistent airflow obstruction (PAO) in patients with asthma can be difficult to treat. Tezepelumab blocks thymic stromal lymphopoietin, an epithelial cytokine implicated in asthma pathogenesis. This analysis evaluated the efficacy of tezepelumab in patients with severe, uncontrolled asthma and PAO. Methods: PATHWAY (phase 2b) and NAVIGATOR (phase 3) were multicentre, randomised, double-blind, placebo-controlled studies. This Results: Of the 1334 included patients, 782 (58.6%) had PAO at baseline. At week 52, greater improvements in pre-bronchodilator FEV Conclusion: Tezepelumab improved lung function and reduced exacerbations

Identifiers

PMID39588080
PMCPMC11587167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.